Company news
Kringle Pharma, Inc. news in 2026
Kringle Pharma, Inc.'s news releases, calls and decks from 2026, newest first.
Kringle Pharma Receives FDA Clearance of IND Application for Oremepermin Alfa in Acute Spinal Cord Injury
October 18, 2026
Kringle Pharma Announces IND Submission to the U.S. FDA for Oremepermin Alfa for the Treatment of Acute Spinal Cord Injury
September 23, 2026
Financial Results for the Nine Months Ended June 30, 2026 [Japanese GAAP] (Non-consolidated)
August 10, 2026
Kringle Pharma Advances the Registrational Program for Oremepermin Alfa in Japan with Initiation of Additional Phase 3 in Acute Spinal Cord Injury
July 23, 2026